CTLA4 and melanoma: These proliferating cells, in addition to the PD1 molecule, expressed high levels of CTLA-4, and this phenomenon makes these cells particularly relevant in the anti-tumor immunity when the anti-PD1 therapies were combined with the anti-CTLA4 antibodies, as shown in melanoma patients (25, 26).